GGrantIndex
Sort

50,496 grants matching lung cancer

Epidemiology of Venous Thrombosis and Pulmonary Embolism

$865,654
Weihong Tang · University Of Minnesota · R01 · FY2022 · HL

NRG Oncology Biospecimen Bank

$865,475
Richard C Jordan · Nrg Oncology Foundation, Inc. · U24 · FY2020 · CA

Mouse Models for Human Cancer

$865,467
Brigham And Women'S Hospital · U01 · FY2005 · CA

Development of Drugs Acting at Adenosine Receptors

$865,266
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK

Modeling Airway Lung Cancer and the Role of Inflammation

$865,166
Francesco John Demayo · Baylor College Of Medicine · U01 · FY2006 · CA

Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells

$865,162
Benjamin Richard Hawley · Engage Biologics Inc. · R44 · FY2025 · TR

CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS

$865,161
Johns Hopkins University · U01 · FY2001 · CA

Sealing Air Leaks by Inductive Coagulation Following Lung Surgery

$865,071
Kevin Marchitto · Rocky Mountain Biosystems, Inc. · R44 · FY2009 · HL

Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform

$865,070
Ian Paul Winters · D2g Oncology, Inc. · R44 · FY2021 · CA

HFH-MSU CSRN ACCrual Enrollment and Screening Site

$864,728
Christine Marie Neslund-Dudas · Henry Ford Health + Michigan State University Health Sciences · UG1 · FY2024 · CA

Harvard/Stanford GTN Program: Novel targeted therapeutics for glioblastoma

$864,597
Tracy T Batchelor · Brigham And Women'S Hospital · U19 · FY2023 · CA

Preclinical Development of a Novel and Powerful Immunotherapeutic

$864,478
Susan Dana Jones · Immurx Llc · R44 · FY2013 · AI

Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factors

$864,461
R.t Jensen · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK

Investigation of lung tumor development and treatment u*

$864,356
Tyler E Jacks · Massachusetts Institute Of Technology · U01 · FY2006 · CA

Dayton Clinical Oncology Program

$864,347
Howard M Gross · Dayton Clinical Oncology Program · U10 · FY2007 · CA

Modeling Airway Lung Cancer and the Role of Inflammation

$863,870
Francesco John Demayo · Baylor College Of Medicine · U01 · FY2007 · CA

Base Excision DNA Repair in Disease Susceptibility and Treatment

$863,862
David Wilson · National Institute On Aging · ZIA · FY2018 · AG

Genes contributing for nicotine dependence in humans

$863,787
Kari Stefansson · Decode Genetics, Ehf · R01 · FY2011 · DA

Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy

$863,755
Jyothi Rengarajan · Emory University · R01 · FY2024 · AI

Tissue factor-dependent coagulation in thrombosis and immune responses

$863,736
Nigel Mackman · Univ Of North Carolina Chapel Hill · R35 · FY2021 · HL

Clinical trials employing cancer vaccine combination therapies

$863,733
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines

$863,733
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Enhancing Cancer Care Of Rural Dwellers Through Telehealth and Engagement (ENCORE)

$863,700
Debra L Friedman · Vanderbilt University Medical Center · R01 · FY2020 · CA

NIH Chronic GVHD Study Group

$863,692
Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Mesothelin-targeted immunotoxins in Pancreatic Cancer

$863,617
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA